Viral respiratory infections in a rapidly changing climate: the need to prepare for the next pandemic

He, Yan; Liu, William J.; Jia, Na; Richardson, Sol; Huang, Cunrui

doi:10.1016/j.ebiom.2023.104593

Cited by 18 publications

(12 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The causes of the anticipation of RSV epidemics may be due to several factors, including the climate change; as a matter of fact, recent epidemiological surveillance in temperate climates has revealed a shift in the peak timing of RSV seasonal activity towards warmer seasons over the past few decades, along with a shortened epidemic duration. 19 However, the seasonality pattern of the last season seems to be realigning to the pre-pandemic seasons, and the 2023-2024 season may confirm this observation.…”

Section: Patients Requiring MVmentioning

confidence: 86%

The increase of bronchiolitis severity in the 2022–2023 season in an Italian tertiary children's hospital: An isolated phenomenon or a warning sign?

Brisca,

Strati,

Buratti

et al. 2024

Pediatric Pulmonology

View full text Add to dashboard Cite

AimRecent literature has shown epidemiological changes in bronchiolitis with an increased incidence in the post‐SARS‐CoV‐2 pandemic period but reports regarding disease severity are conflicting. We aimed to describe the epidemiology, disease severity, and microbiology of bronchiolitis during the 2022–2023 cold season compared to the previous 5 years.MethodsThis single‐center retrospective observational study at IRCCS Gaslini, Italy, included all children aged 0–2 years hospitalized for bronchiolitis from 1 September 2017 to 31 August 2023. Findings from the 2022–2023 season were compared to the previous 5 years.ResultsWe observed a statistically significant increase in the 2022–2023 season in the absolute number of bronchiolitis admissions. Children who required mechanical ventilation (MV) dramatically increased from a total of seven patients in the previous five seasons to 17 in the 2022–2023 season alone (p = .001). All other severity parameters significantly increased: the need for respiratory support (p = .002), the median length of stay (5 days vs. 4 days, p = .001), and the median duration of respiratory support (4 days vs. 3 days, p = .016).ConclusionsWe report a substantial increase in the severity of bronchiolitis in the season 2022–2023 with a remarkable number of previously healthy infants requiring MV. Further studies are needed to confirm whether our findings are an isolated phenomenon or part of a true global trend. Health systems need to be prepared and protective preventive measures should be implemented for all newborns.

show abstract

Section: Patients Requiring MVmentioning

confidence: 86%

The increase of bronchiolitis severity in the 2022–2023 season in an Italian tertiary children's hospital: An isolated phenomenon or a warning sign?

Brisca,

Strati,

Buratti

et al. 2024

Pediatric Pulmonology

View full text Add to dashboard Cite

show abstract

“…Urban development and increased trade lead to economic and societal gains, but also trigger potential changes in arboviruses epidemiology necessitating a cross-country collaboration and mitigation strategies. On the other hand, biological, socioeconomic, and ecological changes increase the risk of viral respiratory infections emergence and transmission worldwide (11).…”

Section: A Target Enrichment Standard Hybridization Workflow Using Tw...mentioning

confidence: 99%

Detection of Chikungunya virus in The Gambia through a newly implemented sentinel surveillance program

Jallow,

Dieng,

Sanneh

et al. 2024

Preprint

View full text Add to dashboard Cite

We characterized 01 autochthonous chikungunya virus (CHIKV) case from (The Gambia) through a newly implemented local arboviruses surveillance program highlighting the first notification of the virus in the Country. Identified virus is closely related to CHIKV West African genotype detected in Kedougou (Senegal) in 2023 and responsible of a large outbreak with up to 300 confirmed cases. This work describes the first genomic proof subregional spread of CHIKV West African genotype in West Africa.

show abstract

“…Respiratory viruses are among the leading causes of morbidity and mortality worldwide. Influenced by human density and mobility, and climate change, these viruses have been responsible for a variety of outbreaks and epidemics with important social and economic consequences [ 1 ]. This has been the case for the severe acute respiratory syndrome (SARS) outbreak in 2003, influenza H1N1 in 2009, Middle East respiratory syndrome (MERS) in 2012 and, most recently, the COVID-19 pandemic.…”

Section: Introductionmentioning

confidence: 99%

Polarised human alveolar epithelia enable identification of dichloroacetate as an effective drug against respiratory viruses

de Iturrate,

Hernáez,

Santos

et al. 2024

Preprint

View full text Add to dashboard Cite

Respiratory viral infections are a significant cause of morbidity and mortality worldwide. The COVID-19 pandemic has highlighted the lack of chemotherapeutic tools available for fighting emerging viruses and the need to focus on preclinical models that better recapitulate human disease. We performed a comparative analysis of inhibitors of the PI3K/AKT/mTOR pathway, which is involved in virus-induced metabolic reprogramming, since strategies aimed at identifying cellular targets could serve to combat diverse viruses and hamper the development of resistance. Tests were performed in two human cell lines, MRC5 lung fibroblasts and Huh7 hepatoma cells, and the results showed that the inhibitors had markedly different effects on energy metabolism and antiviral activity. Thus, dichloroacetate (DCA) has potent antiviral activity against HCoV-229E in MRC5 cells but not in Huh7 cells, suggesting that the screening model is more critical than previously assumed. DCA was then tested in polarized human alveolar epithelia in air-liquid interface, a 3D model used to study respiratory infections. DCA reduced the viral progeny of HCoV-229E, SARS-CoV-2 and respiratory syncytial virus by 2-3 orders of magnitude, and it was effective even when applied once infection had been established. Although DCA has previously been shown to be effective against other viruses, suggesting that it could be a broad-spectrum antiviral, our experiments reinforce the need to use physiologically appropriate disease models to screen antiviral compound.

show abstract

Viral respiratory infections in a rapidly changing climate: the need to prepare for the next pandemic

Cited by 18 publications

References 93 publications

The increase of bronchiolitis severity in the 2022–2023 season in an Italian tertiary children's hospital: An isolated phenomenon or a warning sign?

The increase of bronchiolitis severity in the 2022–2023 season in an Italian tertiary children's hospital: An isolated phenomenon or a warning sign?

Detection of Chikungunya virus in The Gambia through a newly implemented sentinel surveillance program

Polarised human alveolar epithelia enable identification of dichloroacetate as an effective drug against respiratory viruses

Contact Info

Product

Resources

About